iPrEx Study: Gladstone Institute

The Chemoprophylaxis for HIV Prevention in Men study, also known as iPrEx, is a Phase III clinical study designed to determine whether a daily tablet containing a combination of two antiretroviral drugs used for HIV treatment can safely and effectively prevent HIV infection among men who have sex with men and transgendered women who have sex with men. The iPrEx study, which began in July 2007, was the first large-scale study under the National Institute of Allergy and Infectious Diseases (NIAID) to investigate the now widely-accepted HIV prevention approach known as pre-exposure prophylaxis, or PrEP.

The randomized, double-blind, placebo-controlled trial enrolled 2,499 men and transgendered women at 11 sites in nine cities in Brazil, Ecuador, Peru, South Africa, Thailand and the United States.

DF/Net has been working with Dr. Grant’s team at Gladstone since 2006.


We use cookies

This website automatically uses the cookies needed to optimize your navigation. To allow additional cookies used to personalize content relevant to you, click “YES, I ACCEPT.”